Replimune Group (NASDAQ:REPL) Shares Up 6% After Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL) shot up 6% during mid-day trading on Wednesday after BMO Capital Markets raised their price target on the stock from $18.00 to $27.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $12.41 and last traded at $12.57. 67,909 shares were traded during trading, a decline of 91% from the average session volume of 795,967 shares. The stock had previously closed at $11.85.

REPL has been the subject of several other research reports. HC Wainwright lifted their price objective on shares of Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $19.14.

Insider Activity at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after acquiring an additional 52,498 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after acquiring an additional 217,308 shares in the last quarter. Barclays PLC grew its position in Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after buying an additional 98,791 shares during the period. LMR Partners LLP grew its position in Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after buying an additional 48,920 shares during the period. Finally, Cubist Systematic Strategies LLC grew its position in Replimune Group by 282.2% during the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after buying an additional 53,313 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

The company has a market cap of $890.83 million, a P/E ratio of -4.27 and a beta of 1.28. The company’s 50-day moving average is $12.18 and its two-hundred day moving average is $11.28. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. Equities analysts predict that Replimune Group, Inc. will post -2.91 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.